Skip to main content
. 2013 Mar 14;8(3):e58955. doi: 10.1371/journal.pone.0058955

Figure 8. Increased serum levels of TIMP-4 and Endoglin in HCV patients with complete liver cirrhosis.

Figure 8

Serum levels of TIMP-4, Endoglin and Pentraxin-3 were comparable and without significant differences between patients with CFLD and those with HCV liver disease (top row, A). In the cohort of patients with HCV liver disease, patients with complete fibrosis/cirrhosis (F = 4) exhibited significantly increased serum levels of TIMP-4 and Endoglin compared those HCV patients with portal fibrosis with few or numerous fibrotic septae but without cirrhosis (F = 2/3), whereas Pentraxin-3 remained unchanged in the different HCV fibrosis stages (bottom row, B).